Switch theme
Sign up to access all valuation multiples
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
2011
26
Last FY Revenue n/a
LTM EBITDA -$55.7M
$561M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Trevi Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$55.7M.
In the most recent fiscal year, Trevi Therapeutics achieved revenue of n/a and an EBITDA of -$47.8M.
Trevi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Trevi Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$55.7M | XXX | -$47.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$54.0M | XXX | -$51.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$50.9M | XXX | -$47.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Trevi Therapeutics's stock price is $7.
Trevi Therapeutics has current market cap of $663M, and EV of $561M.
See Trevi Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $561M | $663M | XXX | XXX | XXX | XXX | $-0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Trevi Therapeutics has market cap of $663M and EV of $561M.
Trevi Therapeutics's trades at n/a EV/Revenue multiple, and -11.7x EV/EBITDA.
Equity research analysts estimate Trevi Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Trevi Therapeutics has a P/E ratio of -13.0x.
See valuation multiples for Trevi Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $663M | XXX | $663M | XXX | XXX | XXX |
| EV (current) | $561M | XXX | $561M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.1x | XXX | -11.7x | XXX | XXX | XXX |
| EV/EBIT | -10.4x | XXX | -10.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.0x | XXX | -13.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTrevi Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Trevi Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Trevi Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Trevi Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Trevi Therapeutics acquired XXX companies to date.
Last acquisition by Trevi Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Trevi Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Trevi Therapeutics founded? | Trevi Therapeutics was founded in 2011. |
| Where is Trevi Therapeutics headquartered? | Trevi Therapeutics is headquartered in United States of America. |
| How many employees does Trevi Therapeutics have? | As of today, Trevi Therapeutics has 26 employees. |
| Who is the CEO of Trevi Therapeutics? | Trevi Therapeutics's CEO is Ms. Jennifer L. Good. |
| Is Trevi Therapeutics publicy listed? | Yes, Trevi Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Trevi Therapeutics? | Trevi Therapeutics trades under TRVI ticker. |
| When did Trevi Therapeutics go public? | Trevi Therapeutics went public in 2019. |
| Who are competitors of Trevi Therapeutics? | Similar companies to Trevi Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Trevi Therapeutics? | Trevi Therapeutics's current market cap is $663M |
| Is Trevi Therapeutics profitable? | Yes, Trevi Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Trevi Therapeutics? | Trevi Therapeutics's last 12 months EBITDA is -$55.7M. |
| What is the current EV/EBITDA multiple of Trevi Therapeutics? | Current EBITDA multiple of Trevi Therapeutics is -10.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
